Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Inks Discovery Deal With Next-Gen Protein Player Pieris

This article was originally published in PharmAsia News

Executive Summary

Privately-held Pieris AG announced April 12 a two-target partnership with Tokyo-based Daiichi Sankyo Co. Ltd. It is the German firm's latest alliance to center upon its proprietary anticalin platform and demonstrate its broad utility, which will be necessary if an acquisition is to transpire, although the company says it's not looking for an exit right now

You may also be interested in...



Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel